<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03308110</url>
  </required_header>
  <id_info>
    <org_study_id>B7921011</org_study_id>
    <secondary_id>2017-002052-88</secondary_id>
    <nct_id>NCT03308110</nct_id>
  </id_info>
  <brief_title>Bioavailability and Food Effect Study of Two Formulations of PF-06650833</brief_title>
  <official_title>A Phase 1, Single Dose, Open Label, Randomized, 5-period Crossover Study To Evaluate The Relative Bioavailability And Food Effect On New Modified Release Tablet Of Pf-06650833 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioavailability and food effect of 2 formulations of PF-06650833 in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Actual">January 11, 2018</completion_date>
  <primary_completion_date type="Actual">December 8, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>0-96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax under high fat meal fed conditions</measure>
    <time_frame>0-96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of PF-06650833 from plasma concentration (if data permits)</measure>
    <time_frame>0-96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast under high fat meal fed conditions</measure>
    <time_frame>0-96 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Relative Bioavailability Cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Relative Bioavailability cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06650833</intervention_name>
    <description>Two formulations of PF-006650833</description>
    <arm_group_label>Relative Bioavailability Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects of nonchild bearing potential and/or male subjects who, at the
             time of screening, are between the ages of 18 and 55 years, inclusive.

          -  Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).

        Exclusion Criteria:

          -  Subjects with any of the following characteristics/conditions will not be included in
             the study:

        Evidence or history of clinically significant hematological, renal, endocrine, pulmonary,
        gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease
        (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the
        time of dosing).

        Any condition possibly affecting drug absorption (eg, gastrectomy).

          -  A positive urine drug test.

          -  History of regular alcohol consumption within 6 months before screening.

          -  Treatment with an investigational drug within 30 days (or as determined by the local
             requirement) or 5 half lives preceding the first dose of investigational product
             (whichever is longer).

          -  Screening supine BP greater than equal to 140 mm Hg (systolic) or more than equal to
             90 mm Hg (diastolic), following at least 5 minutes of supine rest.

          -  Pregnant female subjects; breastfeeding female subjects; female subjects of
             childbearing potential;

          -  Use of prescription or nonprescription drugs and dietary supplements within 7 days or
             5 half lives (whichever is longer) prior to the first dose of investigational product.

          -  History of tuberculosis or active or latent or inadequately treated infection,
             positive QuantiFERON-TB Gold test.

        History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive
        testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody
        (HepBcAb), or hepatitis C antibody (HCVAb).

        -Other acute or chronic medical or psychiatric condition including recent (within the past
        year) or active suicidal ideation or behavior or laboratory abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Clinical Research Unit</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7921011&amp;StudyName=A+Phase+1%2C+Single+Dose%2C+Open+Label%2C+Randomized%2C+5-period+Crossover+Study+To+Evaluate+The+Relative+Bioavailability+And+Food+Effect+On+New+Modified+Release+Tablet+Of+Pf-06650833+In+Healthy+Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>October 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2017</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

